Published Date: 17 Feb 2023
China: Low-dose colchicine helps protect myocardium in surgery patients without CABG (coronary artery bypass graft).
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP
2.
examining differences in the rates of breast reconstruction following mastectomies.
3.
Having dense breasts is linked to cancer, but advice about breast density can depend on where you live
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?
1.
The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025
2.
Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management
3.
Lymphomatoid Papulosis: What You Need to Know
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Personalized Cancer Vaccines and Neoantigen mRNA: A New Era in Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XVI
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation